Developing Effective Cancer Vaccines Using Rendered-Inactive Tumor Cells

Overview

Journal Vaccines (Basel)

Date 2023 Aug 26

PMID 37631898

Authors

Shushu Zhao

Shuting Wu

Sheng Jiang

Gan Zhao

Bin Wang

Affiliations

Soon will be listed here.

Abstract

Cancer is a major public health threat, and researchers are constantly looking for new ways to develop effective treatments. One approach is the use of cancer vaccines, which work by boosting the body's immune system to fight cancer. The goal of this study was to develop an effective cancer vaccine using rendered-inactive tumor cells. A CMS5 fibrosarcoma tumor model in BALB/c mice and an E.G7 lymphoma tumor model in C57BL/6 mice were used to evaluate how mitomycin C-inactivated tumor cells mediated tumor protection. The results showed that immunization with inactivated CMS5 cells significantly improved tumor suppression after a challenge with live CMS5 tumor cells, but no effect was observed using the E.G7 tumor model. The results suggested that DC (dendritic cell) responses to tumor antigens are critical. The maturation and activation of DCs were effectively promoted by mitomycin C-treated CMS5 cells, as well as enhanced phagocytosis ability in vitro. The tumor-protective effects established by the vaccination of inactivated CMS5 cells were CD8+ T cell-dependent, as the antitumor responses disappeared after eliminating CD8+ T cells. It was found that the tumor-prevention efficacy was dramatically increased by combining inactivated CM55 tumor cells with anti-CD25 antibodies to temporarily deplete Treg cells (regulatory T cells). This strategy could also significantly induce the rejection against E.G7 tumors. In addition, vaccination with anti-CD25 antibodies plus inactivated CMS5 cells elicited antitumor responses against heterologous tumors. According to the findings of this study, combining the immunization of inactivated tumor cells with an anti-CD25 antibody may be an effective method for cancer prevention.

References

Tanaka A, Sakaguchi S . Regulatory T cells in cancer immunotherapy. Cell Res. 2016; 27(1):109-118. PMC: 5223231. DOI: 10.1038/cr.2016.151. View

Roberts E, Broz M, Binnewies M, Headley M, Nelson A, Wolf D . Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell. 2016; 30(2):324-336. PMC: 5374862. DOI: 10.1016/j.ccell.2016.06.003. View

Ohue Y, Nishikawa H . Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Sci. 2019; 110(7):2080-2089. PMC: 6609813. DOI: 10.1111/cas.14069. View

Zhang X, Cui H, Zhang W, Li Z, Gao J . Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison. Bioact Mater. 2022; 22:491-517. PMC: 9619151. DOI: 10.1016/j.bioactmat.2022.10.016. View

Maeng H, Berzofsky J . Strategies for developing and optimizing cancer vaccines. F1000Res. 2019; 8. PMC: 6518434. DOI: 10.12688/f1000research.18693.1. View

Oresta B, Pozzi C, Braga D, Hurle R, Lazzeri M, Colombo P . Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer. Sci Transl Med. 2021; 13(575). DOI: 10.1126/scitranslmed.aba6110. View

Vargas F, Furness A, Solomon I, Joshi K, Mekkaoui L, Lesko M . Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity. 2017; 46(4):577-586. PMC: 5437702. DOI: 10.1016/j.immuni.2017.03.013. View

Lai-Lai Chiang C, Benencia F, Coukos G . Whole tumor antigen vaccines. Semin Immunol. 2010; 22(3):132-43. PMC: 3119500. DOI: 10.1016/j.smim.2010.02.004. View

Lamberti M, Nigro A, Casolaro V, Rumie Vittar N, Dal Col J . Damage-Associated Molecular Patterns Modulation by microRNA: Relevance on Immunogenic Cell Death and Cancer Treatment Outcome. Cancers (Basel). 2021; 13(11). PMC: 8197279. DOI: 10.3390/cancers13112566. View

10.

Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X . Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022; 15(1):28. PMC: 8931585. DOI: 10.1186/s13045-022-01247-x. View

11.

Thi V, Jeon H, Park S, Lee H, Kim Y . Cell-Based IL-15:IL-15Rα Secreting Vaccine as an Effective Therapy for CT26 Colon Cancer in Mice. Mol Cells. 2019; 42(12):869-883. PMC: 6939657. DOI: 10.14348/molcells.2019.0188. View

12.

Dhodapkar M, Dhodapkar K, Palucka A . Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ. 2007; 15(1):39-50. PMC: 2762352. DOI: 10.1038/sj.cdd.4402247. View

13.

Chen B, Zhao J, Zhang D, Zheng A, Wu G . Immunotherapy of Cancer by Targeting Regulatory T cells. Int Immunopharmacol. 2022; 104:108469. DOI: 10.1016/j.intimp.2021.108469. View

14.

Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F . Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019; 18(1):128. PMC: 6708248. DOI: 10.1186/s12943-019-1055-6. View

15.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

16.

Ohmura Y, Yoshikawa K, Saga S, Ueda R, Kazaoka Y, Yamada S . Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy. Oncol Rep. 2008; 19(5):1265-70. View

17.

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

18.

Diao L, Liu M . Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell. Adv Sci (Weinh). 2023; 10(22):e2300121. PMC: 10401146. DOI: 10.1002/advs.202300121. View

19.

Solomon I, Amann M, Goubier A, Vargas F, Zervas D, Qing C . CD25-T-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nat Cancer. 2021; 1(12):1153-1166. PMC: 7116816. DOI: 10.1038/s43018-020-00133-0. View

20.

Terme M, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J . Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol. 2013; 2012:492920. PMC: 3540780. DOI: 10.1155/2012/492920. View